Why You Should Not Start An OTC Brand In India, And What To Do If You Have Already Decided
Written by Sudhanshu Soumyan and Google Gemini
Sometimes a horrible pitch meeting leads you to write a cautionary tale in the interest of the public. This is one of them.
This is based on a recent pitch we made to a well-known nutraceutical (Over-the-counter) client. They had a specific brief: Create a brand campaign strategy. As per our methodology, we asked them to present their business strategy for the next 3 years so that we could align the brand strategy and the specific brand campaign to it. Their first reaction, as usual, was almost a 'How dare you ask!' kind. But when they relented, we at Brandroid Consultancy were in for a shock. They presented just a business plan and sales plan. The strategic piece was totally lacking. Their business model had gaping pitfalls. Not surprisingly, the business numbers showed degrowth.
We were shocked.
Holding on to the silence over a virtual meeting can be deafening. Finally, I had to break the silence: "How will this campaign help your brand?" I asked. "This will increase brand awareness and Top-of-the-mind unassisted recall." the brand manager replied. "Will this convince customers to buy your brand?" I asked. "Of course. Our historical data shows that every time we deploy a campaign, our brand indicators go up. I thought to myself: that is like saying that people know about a cheap substitute; their consumers recall it. But will they actually buy that cheap, low-perception brand over a high-perception one?! Really? We excused ourselves from the campaign pitch with a simple "our visions do not align" email. Later, I reflected back on the entire episode and realised, if this company is not doing well even after 30+ years in business, what will happen to a startup founder who does not have the real problems in sight?
So, if you are looking at market reports that show a booming Indian market for preventive health then be ready for a silent awakening. These numbers look great on a spreadsheet: Indian consumers are buying more vitamins, joint pain oils, gut health powders, and herbal supplements than ever before. Market reports have projected double-digit growth annually for consumer health, driven by increasing health awareness among the urban population and the proliferation of digital retail platforms.
So, before you invest your hard-earned life savings, rent a factory space, buy machinery, or make any commitments to third-party vendors/manufacturers, you need to take a macro perspective and examine the reality.
The first thing I advise people is: do not follow the VC investment trends. There is a hidden rationale for why they have invested and are probably working on the shortcomings of the specific brand and/or the sector in general.
It does not matter if you are thinking of any of these types of OTC products to carve your niche: ayurveda-based proprietary medicines, natural ingredient-based nutraceuticals, dietary supplements, or topical wellness formulations; the hurdles seem insurmountable. This is especially true for founders who have no prior pharmaceutical experience or nutraceuticals background.
Another reality is the distribution aspect. Go to any chemist near you and you find that the large pharmaceutical/nutraceuticals companies/legacy consumer goods companies dominate their shelves and stock.
The regulatory definitions can be confusing.
Working capital gets tied down to serve only production.
Then there is the difference between the buying behaviour of consumers and what they say in surveys. I will be writing about this at length in another article, as this is universally true for all sectors.
If you have not started investing in people, infrastructure, and systems, my suggestion is to read this article till the end. Even if have, this article may still be helpful to you for changing your path to a successful OTC venture.
The Indian OTC Landscape: A STEEPLE Analysis
To understand the landscape of OTC sector in India, let us first deep-dive into the factors that affect it. I will use the simple STEEPLE (Social Technological, Economic, Environmental, Political, Legal, and Ethical) framework to identify barriers and gaps you may face. Each factor is followed by a practical solution to help you navigate your business.
A) Social Factors
The Problem: Chemist Gatekeeping and the Expectation of Immediate Relief
When an Indian feels unwell or needs a personal remedy, they rarely start by searching online for a solution or a specific brand. She/he simply walks into their local chemist shop and ask the friendly chemist for advice. That is why in India, retail chemists hold immense authority over which remedy gets recommended. And it also changes from one chemist to the other. So, If a customer asks for a digestive syrup or a topical joint pain spray, the chemist hands her/him an established legacy brand or a generic drug that gives the chemist a fat 40% margin. Your new brand may not even enter the conversation. How will your brand break this chain?
Indian consumers expect rapid relief of symptoms all thanks to allopathic medicines. Even if, say, they take a non-allopathic pain-relief medicine/treatment, they want the symptoms to disappear within half an hour just like an allopathic formulation. that is why a lot of people discontinue an ayurvedic formulation and never try it again.
The Solution: Standardized Bioactives and Counter Alignment
Create formulations with noticeable fast effects: Relying on the formulation to take months to show results may be too idealistic. Adding ingredients that offer immediate, sensory or physiological relief or action to the essential formulation can help achieve 'instant' action. Example: If you manufacture a topical pain relief balm, combine classical botanical extracts like Boswellia serrata with natural wintergreen oil (Gaultheria) or menthol to create immediate cooling relief till such time the active compounds in your formulation starts working at a deeper level.
Negotiate the best possible terms with the chemists: Pharmacy chains stock centrally and the margins big brands commit based on volumes decide what they offer to their customers. Independent pharmacies on the other hand, stock as per the relationship you have with them and they can generate demand for you by recommending your brand over others. Provide them with proper product documentation, attractive retail display boxes that stand out among crowded counters, and, of course margins that compete with regional wholesale distributors.
Educate the customer on overall wellness, lesser chances of side effects, and realistic physiological timelines: On the packaging and any communication emphasise on the end benefits and less chances of side effects from your formulations. Clearly show certifications. How does your product work in the body and how to use it should be in a nice leaflet with text in large font size. If you have conducted a genuine clinical trial, add it to the leaflet and mention the jist - this clinical trial showed that on an average the benefits start showing by the fourteenth day.
B) Technological Factors
The Problem: Bioavailability, Thermal Instability, and Climate Stress
As you know, that Botanical/herbal/natural extracts are delicate. Stabilising them is tough. Phytochemicals like curcuminoids, withanolides, and silymarin suffer from low bioavailability when taken orally. The human gut excretes most of the active molecules without absorbing them into the bloodstream when consumers take them in crude powder form.
India's harsh climatic conditions adds to your woes. According to international stability standards, India falls within Climatic Zone IVb. This requires stability testing at 40°C and 75% relative humidity. When you use transport vehicles that are not insulated (which is the case with most of them), and they travel through northern India's summer heat or coastal humidity, formulations like nutritional softgels, herbal effervescent tablets, or topical creams degrade. Tablets can absorb ambient moisture inside blister packs. Plant oils oxidise and turn rancid, giving a foul smell. Probiotic bacteria strains can die long before your product reaches the consumer'.
The Solution: Standardised Extracts, Delivery Systems, and Barrier Packaging
Use standardised botanical extracts rather than crude powders or raw plant material. Only procure extracts that guarantee verified marker concentrations through High-Performance Thin-Layer Chromatography (HPTLC) or HPLC testing. Examples: 95% total curcuminoids or 5% withanolides.
Add bio-enhancers: Your Formulations should include absorption enhancers, such as piperine (Piper nigrum extract) or phospholipid complexes. These enhance intestinal permeability and absorption of the main active molecules.
Zone IVb accelerated stability testing: Test your final batches at 40°C and 75% relative humidity for a full six months. Only then start before releasing them for commercial distribution. This may be time-consuming and may sound wasteful, but it is crucial.
Select high-barrier packaging materials only: This may add to your costs, but it will also help you deliver your promise of an effective product within its expiry date. For sensitive oral formulations, use cold-form aluminium-aluminium (Alu-Alu) blisters or amber glass containers with induction-sealed heat liners and silica desiccant canisters to block light and humidity.
Beat the Chemist and the distributors at their own game: If you plan to launch your brand with multiple products, you can create your own online e-commerce store and deliver pan-India. This circumvents the distribution hurdles and some of the logistic hurdles.
C) Economic Factors
The Problem: High Trade Margins, Vendor's Minimum Order Guarantees, and Working Capital loss
The cost structure of Indian health retail exhausts young consumer brands. Traditional pharmaceutical distribution requires multiple layers of middle-tier partners:
Super-stockists demand 6% to 8% margin.
Stockists and distributors demand 10% to 15% margin.
Retail chemists demand 20% to 30% margin.
When you add modern pharmacy chains and quick-commerce platforms, commissions climb to 35% or 48%, accompanied by listing fees for every stock-keeping unit (SKU) and mandatory promotional fees.
Distributors routinely ask for 60 to 90 days of credit. If your product does not sell off store shelves quickly, distributors stop paying for past shipments and return unsold stock near its expiry date. Meanwhile, third-party contract manufacturers enforce Minimum Order Quantities (MOQs) of 5,000 to 10,000 units per SKU. You must pay for packaging, raw materials, and manufacturing upfront, locking your liquid capital into finished goods while you wait months to collect customer payments.
Financial Item | Typical Percentage of MRP | Impact on a ₹500 OTC Product |
Maximum Retail Price (MRP) | 100% | ₹500.00 |
Retailer & Distributor Margin | 42% | -₹210.00 |
Manufacturing & Packaging (COGS) | 22% | -₹110.00 |
Logistics, Freight & Spoilage | 10% | -₹50.00 |
Performance Ads & Channel Promotion | 20% | -₹100.00 |
Founder Operating Margin | 6% | ₹30.00 |
The Solution: Margin Architecture and Staged Manufacturing
Protect your gross margins from day one: Your manufactured cost of goods sold, including active ingredients, bottles, caps, and cartons, must not exceed 20% to 25% of your final retail price. If your production cost climbs to 35%, you will not have enough operating margin to survive retail distributor cuts and marketing expenses.
Negotiate split packaging runs with manufacturers: Contract with manufacturing partners who allow you to blend a bulk production batch while printing and packaging finished containers in smaller, staged runs based on real sales velocity.
Enforce strict credit caps: Do not extend credit past 45 days to any distributor, regardless of their size. Halting supply to an overdue stockist protects your business; sending more inventory to a non-paying distributor guarantees bad debt.
D) Environmental Factors
The Problem: Agricultural Contamination and Waste Regulations
The agricultural supply chain for medicinal herbs in India faces structural quality issues. Soil depletion, industrial runoff, and unchecked pesticide use mean that raw plants frequently contain elevated levels of heavy metals (lead, cadmium, arsenic, and mercury). Herbs harvested along highway corridors or contaminated river basins absorb systemic toxins that concentrate when raw material is processed into extracts.
Simultaneously, the Central Pollution Control Board (CPCB) enforces strict Extended Producer Responsibility (EPR) regulations under the Plastic Waste Management Rules. Every brand owner selling packaged goods in plastic bottles, blister cards, or tubes must register on the national CPCB portal, track their total plastic footprint by weight, and purchase verified plastic recycling credits. Non-compliance brings operational penalties and formal notices from state pollution boards.
The Solution: Heavy Metal Testing and EPR Integration
Enforce strict raw material testing: Test every single lot of raw herbs and active botanicals using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Ensure that your heavy metal concentrations remain well below the statutory thresholds specified in the Ayurvedic Pharmacopoeia of India.
Source from audited cultivators: Purchase your botanicals from suppliers who adhere to Good Agricultural and Field Collection Practices (GACP).
Automate your EPR compliance: Register your enterprise on the CPCB portal during product development. Partner with an authorized waste management agency to purchase verified plastic disposal credits each quarter.
E) Political Factors
The Problem: The Jurisdictional Rift Between AYUSH and FSSAI
In India, consumer health formulations fall under two distinct regulatory authorities: the Ministry of AYUSH and the Food Safety and Standards Authority of India (FSSAI).
The boundaries between an Ayurvedic medicine and a nutraceutical food supplement can be ambiguous. Certain botanical ingredients (such as ashwagandha, moringa, and amla) are permitted under both frameworks, but with differing dosage limits and label requirements. When regulatory authorities issue conflicting notifications regarding permitted botanicals or therapeutic classifications, brands get caught in jurisdictional disputes.
Additionally, the National Pharmaceutical Pricing Authority (NPPA) monitors medical products. If an active ingredient gets classified under the National List of Essential Medicines (NLEM), the government can impose strict price caps through the Drugs (Prices Control) Order (DPCO), limiting your ability to adjust prices.
The Solution: Unambiguous Statutory Classification
Choose a single regulatory identity: Decide whether your product is an Ayurvedic Proprietary Medicine or an FSSAI Nutraceutical before finalizing formulations. Do not attempt to blend standards. If you license under AYUSH, formulate strictly according to classical texts recognized in the First Schedule of the Drugs and Cosmetics Act. If you license under FSSAI, comply precisely with the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, etc.) Regulations.
Audit domestic ingredient sources: Maintain secondary domestic suppliers for every active ingredient. Avoid formulations that depend entirely on imported specialty botanicals that are vulnerable to shifting customs tariffs or port inspections.
F) Legal Factors
The Problem: The Non-Existent "OTC" Category and Advertising Laws
Indian statutory law does not contain a formal legal definition for "Over-The-Counter."
Under the Drugs and Cosmetics Act of 1940 and the Drugs Rules of 1945, every pharmaceutical formulation is legally classified as a drug. Drugs require a licensed retail pharmacy and a medical prescription for sale, unless they are specifically exempted under Schedule K of the Rules. While Ayurvedic proprietary medicines and FSSAI-registered health supplements can be sold without a prescription, you cannot make medical claims freely.
The Drugs and Magic Remedies (Objectionable Advertisements) Act of 1954 prohibits any commercial advertising that claims to prevent, diagnose, or cure 54 specific clinical conditions, including diabetes, high blood pressure, arthritis, kidney disorders, and obesity. The Central Consumer Protection Authority (CCPA) and the Advertising Standards Council of India (ASCI) actively penalize consumer brands that make unverified health claims on television, print media, or digital advertisements.
The Solution: Conservative Claim Architecture and Regulatory Review
Focus on structure and function, not disease treatment: Frame your label copy and advertising messages around supporting physiological health rather than curing clinical conditions. Use terms like "supports joint flexibility" instead of "treats arthritis," or "helps maintain balanced blood sugar" instead of "reverses diabetes."
Compile a substantiation dossier: Maintain clinical research papers and laboratory stability reports for every health claim you publish on your packaging or website.
Have a regulatory attorney review your packaging: Submit your packaging layout, ingredient lists, and marketing copy to a seasoned pharmaceutical regulatory lawyer before printing your commercial packaging.
G) Ethical Factors
The Problem: Adulteration Scandals and Consumer Skepticism
The Indian consumer health sector has suffered repeated scandals involving adulterated formulations. Unethical manufacturers have spiked topical pain relief oils with synthetic allopathic anti-inflammatory drugs like diclofenac, added sildenafil to vitality products, or mixed corticosteroids into herbal skin creams to produce rapid, temporary effects.
When government testing laboratories detect these adulterants and publish the results, consumer trust in the entire category declines. Modern Indian consumers are increasingly skeptical of sensational marketing claims. If an educated buyer notices that your product claims to be "100% Herbal" while concealing synthetic preservatives behind vague terms on the back label, they will call out the brand on social channels.
The Solution: Full Ingredient Disclosure and Third-Party Lab Audits
Publish full ingredient transparency: List every component on your product label, including active botanicals, binders, preservatives, and capsule shell materials. Use standardized botanical and chemical nomenclature. Avoid misleading phrases like "100% chemical-free."
Provide public batch certificates: Run independent chemical screens on every finished production lot at an accredited testing laboratory. Publish the Certificate of Analysis (CoA) on your website, confirming that the product is free from allopathic adulterants, synthetic steroids, microbial growth, and heavy metals.
OTC Formulations: Common Misconceptions vs. Scientific Reality
Many consumer health founders build business models around assumptions that contradict biological and chemical facts. Use this comparison to evaluate your product strategy.
Common Consumer & Brand Misconception | Biochemical & Pharmacological Reality | Practical Commercial Impact in India |
"Because an ingredient is plant-based, it cannot cause adverse side effects." | Plants contain active secondary metabolites, such as alkaloids and glycosides. Excessive doses of botanical extracts like Cassia angustifolia (senna) or high-potency Withania somnifera (ashwagandha) can cause digestive irritation or liver strain in sensitive individuals. | Consumers self-medicate with high doses, experience side effects, stop using the product, and leave negative public reviews. |
"A larger milligram dose of crude root powder works better than a small extract dose." | Crude botanical powders consist mostly of insoluble plant cellulose and non-active structural matter. A 200 mg dose of a standardized extract containing 50% bioactive markers delivers far greater therapeutic value than 1,500 mg of unstandardized crude powder. | Formulations packaged into oversized, difficult-to-swallow tablets fail to produce clinical benefits, resulting in poor repeat customer retention. |
"Topical Ayurvedic oils absorb through the skin into deep joint tissues on their own." | The skin's outer layer, the stratum corneum, blocks molecules larger than 500 Daltons. Most botanical polyphenols cannot penetrate past the epidermis into joint capsules without specific absorption enhancers or carrier lipids. | Topical products provide only surface-level lubrication, failing to deliver long-term relief unless formulated with natural skin-permeation enhancers. |
"An FSSAI nutraceutical license allows you to market preventive medical treatments." | FSSAI licenses cover dietary supplements designed to maintain normal physiological nutrition. Claiming that a nutraceutical treats, cures, or mitigates a specific clinical disease violates FSSAI rules and triggers regulatory penalties under the Drugs and Cosmetics Act. | State drug inspectors can issue stop-sale notices, seize retail inventory, and initiate court proceedings against company directors. |
What to Do if You Have Already Decided to Launch
If you have already spent capital, formulated your batches, and committed yourself to building this brand, follow these four defensive operating principles:
Rebuild your financial model with realistic retail costs: Recalculate your margins assuming a 45% retailer discount, a 10% distributor margin, a 12% freight and damage allowance, and an 80-day cash collection cycle. If your unit contribution margin is negative under these conditions, raise your retail price or adjust your bottle sizes immediately before shipping inventory.
Focus on a specific, high-intent consumer problem: Do not try to launch a generic multivitamin or a general vitality syrup to compete with established pharmaceutical brands. Solve a specific problem for an underserved consumer group, such as targeted nutritional support for postpartum recovery, non-steroidal joint care for active runners, or sleep formulations for shift workers.
Commission independent clinical efficacy dossiers: Invest in human clinical trials or double-blind studies on your finished production formula at an accredited contract research organization. Having verified clinical data sets your brand apart from generic formulations and provides legal protection against advertising complaints.
Prove customer retention through direct channels first: Sell your initial production runs through your own digital storefront and select health practitioners. Focus on achieving a 90-day repeat purchase rate above 25%. Once you prove that consumers come back to buy your product without heavy discounting, you can negotiate with retail distributors from a position of commercial strength.
Sources & Scientific References
Pharmacokinetics, Bioavailability, and Standardization of Botanicals:
Bioavailability Enhancement Strategies for Botanical Bioactives: Research papers from the Journal of Controlled Release evaluating lipid-based formulations, phytosomes, and natural bio-enhancers (such as piperine) in improving systemic absorption of polyphenolic compounds.
World Health Organization (WHO): "Quality Control Methods for Herbal Materials." Technical monographs detailing chromatographic fingerprinting (HPTLC and HPLC) and quantitative determination of active marker compounds in botanical medicines.
Heavy Metal Contamination and Safety Limits in Herbal Formulations:
Ayurvedic Pharmacopoeia of India (API): Statutory permissible limits for lead, cadmium, mercury, and arsenic in botanical raw materials and finished traditional formulations.
International Conference on Harmonisation (ICH) Guidelines: Guideline Q3D on Elemental Impurities, outlining toxicological safety thresholds and risk assessments for oral health products.
Topical Permeation Kinetics:
The 500 Dalton Rule for Skin Permeation: Fundamental dermatological research published in Experimental Dermatology detailing molecular weight limitations and lipid partition coefficients (log P) governing dermal absorption through the human stratum corneum.
Indian Statutory and Regulatory Frameworks:
The Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945: Statutory provisions governing Section 3(a) (Ayurvedic, Siddha, or Unani drugs), Section 33EEB (manufacturing standards), and Schedule K non-prescription exemptions.
Food Safety and Standards Authority of India (FSSAI): Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, and Prebiotic and Probiotic Food) Regulations.
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954: Schedule of 54 prohibited diseases and statutory restrictions on therapeutic claims in commercial advertising.
The Consumer Protection Act, 2019 and Central Consumer Protection Authority (CCPA) Guidelines: Mandatory substantiation standards for commercial consumer health claims and administrative penalties for misleading promotional material.
Comments